Clinical Trials in Yokohama, Kanagawa-ku
8 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
Study of Out of Specification for Tisagenlecleucel
Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals200 enrolled53 locationsNCT04094311
Recruiting
Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)
Pediatric Chronic Heart Failure
Novartis Pharmaceuticals30 enrolled28 locationsNCT06659393
Recruiting
Phase 3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Novartis Pharmaceuticals550 enrolled127 locationsNCT06133972
Recruiting
Phase 2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals200 enrolled127 locationsNCT06470048
Recruiting
Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Prostate Cancer
Novartis Pharmaceuticals940 enrolled55 locationsNCT06855277
Recruiting
Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Lupus Erythematosus, SystemicLupus Nephritis
Novartis Pharmaceuticals179 enrolled93 locationsNCT06581198
Recruiting
Phase 2
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals123 enrolled55 locationsNCT06665256
Recruiting
Special Drug Use-results Surveillance of Tafinlar/Mekinist
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis Pharmaceuticals110 enrolled68 locationsNCT06262919